Document is current
Any future updates will be listed below
-
Authors
Huuhtanen, Jani https://orcid.org/0000-0003-2750-4033
Bhattacharya, Dipabarna
Lönnberg, Tapio https://orcid.org/0000-0003-4484-5657
Kankainen, Matti https://orcid.org/0000-0002-4714-9481
Kerr, Cassandra
Theodoropoulos, Jason
Rajala, Hanna https://orcid.org/0000-0003-2675-2385
Gurnari, Carmelo https://orcid.org/0000-0001-6829-5544
Kasanen, Tiina
Braun, Till
Teramo, Antonella https://orcid.org/0000-0002-2754-699X
Zambello, Renato https://orcid.org/0000-0002-8799-5324
Herling, Marco
Ishida, Fumihiro https://orcid.org/0000-0002-0525-7636
Kawakami, Toru https://orcid.org/0000-0003-0178-5332
Salmi, Marko
Loughran, Thomas
Maciejewski, Jaroslaw P. https://orcid.org/0000-0002-6837-4346
Lähdesmäki, Harri
Kelkka, Tiina https://orcid.org/0000-0003-1085-6382
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
-
Funding
Funding for this research was provided by:
Academy of Finland
Signe ja Ane Gyllenbergin Säätiö
- License Information
-
More Information
Article History
Received: 14 June 2021
Accepted: 17 February 2022
First Online: 11 April 2022
Competing interests
: T.L. is a member of the scientific advisory boards and hold stock options of Keystone Nano, Dren Bio, and Kymera Therapeutics (not related to this project). S.M. has received honoraria and research funding from BMS and research funding from Novartis and Pfizer (not related to this project). The remaining authors declare no competing interests.
